Menu
We are dedicated to Advance our Products to IND and Phase I by either out licensing or seed investments with partners.
GSKure plans to enter the market through orphan disease therapeutics in the field of of Huntington’s and Fragile X syndrome as the financial incentives and benefits given in FDA and EMA regulations for orphan diseases therapeutic development is an encouraging factor. Though, keeping the opportunity to expand into the therapeutic market of neurodegenerative disorders in a later phase.
Kure compounds were validated in several in vivo mouse models of neurodegeneration. Safety studies as well as pharmacological characterization including compound stability, permeability and PK were done in rodents.
We are dedicated to Advance our Products to IND and Phase
I by either outlicensincing or seed investments with partners.
GSKure plans to enter the market through orphan
disease therapeutics in the field of of Huntington’s and Fragile X syndrome as the financial incentives and benefits given in FDA and EMA regulations for orphan diseases therapeutic development is an encouraging factor. Though, keeping the opportunity to expand into
the therapeutic market of neurodegenerative disorders in a later phase.
Kure compounds were validated in several in vivo mouse models of neurodegeneration. Safety studies as well as pharmacological characterization including compound stability, permeability and PK were done in rodents.